Cencora (NYSE:COR) has outperformed the market over the past 10 years by 6.29% on an annualized basis producing an average annual return of 19.83%. Currently, Cencora has a market capitalization of $59.16 billion.
Cardinal Health stock hit a new all-time high after mixed earnings, with analyst price target hikes, gene therapy logistics wins and a 29-year dividend growth streak supporting the uptrend.
Cencora’s second quarter was marked by performance that met Wall Street’s expectations on revenue and exceeded consensus on non-GAAP profitability, driving a...
Cencora (NYSE:COR) reported fiscal 2026 third-quarter results marked by double-digit adjusted operating income growth, specialty-business momentum and $1 billion in share repurchases, prompting the pharmaceutical services company to raise its full-year adjusted earnings outlook.
Adjusted operating
Healthcare distributor Cencora (NYSE:COR) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.1% year on year to $84.75 billion. Its non-GAA...
Healthcare distributor Cencora (NYSE:COR) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 5.1% year on year to $84.75 billion. Its non-GAA...
Cencora, Inc. (NYSE: COR) reported that in its fiscal year 2026 third quarter ended June 30, 2026, revenue increased 5.1 percent year-over-year to $84.8 billion. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $3.94 for the third quarter of fiscal 2026 compared to $3.52 in the prior year third quarter. Adjusted diluted EPS, which is a non-GAAP financial measure that excludes items described below, increased 12.0 percent to $4.48 in the fiscal third quarter from $4.00 in the prior year third quarter.
Healthcare distributor Cencora (NYSE:COR) will be reporting earnings this Wednesday before market hours. Here’s what you need to know. Cencora missed analyst...
McKesson posted strong fiscal 2026 results, raised guidance, boosted buybacks and its dividend, and maintains a Moderate Buy rating from analysts amid its evolving specialty business mix.
Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Cencora (NYSE:COR) and its pe...
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ...
Cencora, Inc. (NYSE: COR) today announced that it plans to release its results for the Third Quarter of Fiscal 2026 on Wednesday, August 5, 2026, prior to the opening of trading on the New York Stock Exchange. The Company will host a conference call to discuss the results at 8:30 a.m. ET on August 5, 2026.
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it m...
Over the past six months, Cencora’s stock price fell to $287.06. Shareholders have lost 15.8% of their capital, which is disappointing considering the S&P 50...
Cencora, Inc. (NYSE: COR) today announced that Silvana Battaglia, Executive Vice President and Chief Human Resources Officer (CHRO), has announced she will retire from the company following a distinguished seven-year tenure. She will be succeeded by Samantha (Sam) Hammock, who will join Cencora as Executive Vice President and CHRO, effective July 13, 2026.
Italian healthcare vials and cartridges maker Stevanato Group and U.S. generic and wholesale pharmaceutical company Cencora are two of the best healthcare buys right now.
NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cencora, Inc. (“Cencora” or the “Company”) (NYSE: COR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Cencora, Inc. (NYSE: COR) today announced Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer of the Company, effective June 29, 2026. Ms. Boratto succeeds James F. Cleary, who will be retiring from his role as Executive Vice President and Chief Financial Officer as previously announced. Mr. Cleary will serve in an advisory capacity through the end of 2026 to help ensure a smooth transition.
